Dialysis patients and cardiovascular problems: Can technology help solve the complex equation?

Patients with end-stage kidney disease undergoing chronic hemodialysis (HD) present higher mortality rates compared with the general population. Once patients are on HD, the risk of cardiovascular death is approximately 30 times higher than in the general population and remains 10-20 times higher after stratification for age, gender, and the presence of diabetes. About half the deaths of patients on dialysis are attributed to cardiovascular causes including coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure. The cardiovascular burden of the HD patient arises from three different sources: risks inherent to the patient and the uremic syndrome, traditional risk factors, and risk factors related to the dialysis therapy. Based on these considerations and the fact that several aspects of the dialysis procedure can either add to the cardiovascular burden or modify the existing burden, new technologies should be directed towards the approach of a potential 'cardioprotective dialysis therapy'; such an approach may be facilitated by the application of new techniques and advanced dialysis machines. Created to make dialysis easy and safe, new machines feature several options that make patient monitoring and online hemodiafiltration therapy routine procedures. These and other features will possibly make dialysis better tolerated and more efficient in protecting patients from undesirable or potentially fatal cardiovascular events.     

Vascular access monitoring: methods and procedures--something to standardize?

The article discusses the issue of suitable parameters (pressures, recirculation and access flow) to assess hemodialysis vascular access quality (VAQ), available methods to measure those parameters and the setup of the entire VAQ surveillance system (VAQS) in a dialysis facility. Special attention is paid to factors which need some standardization to enable evaluation of VAQ trends in an individual as well as comparison of data from different patients and different dialysis facilities. The discussed procedures are documented with the authors' own measurement results and the results of the VAQS implemented in their unit. Both dynamic and static pressures exhibit insufficient sensitivity in detecting stenoses in native arteriovenous fistulas. Access recirculation is a late finding because with its non-zero value dialysis quality is already compromised. Timely and reliable detection of a deteriorating access condition is enabled by access flow (QVA) only. No standardization is needed in extracorporeal blood flow used in QVA evaluation by ultrasonic dilution. Multiple measurements may increase the reliability of thermodilutional measurements and are a must in optodilutional ones. Timing of the measurement during dialysis should be standardized. Measurement frequency should take into account access type, QVA value and access history. Shortened intervals are needed in the immediate post-intervention period with regard to risk of re-stenosis incidence and strongly nonlinear QVA decreases in such cases. A significant shift-over from surgical interventions to balloon angioplasties is to be expected with the introduction of a VAQS, and appropriate measures must be taken to ensure their quick availability.     

What are the anticoagulation options for intermittent hemodialysis?

Prevention of clotting in the extracorporeal circuit was one of the major hurdles that had to be overcome to enable the expansion of routine outpatient hemodialysis to free-standing satellite centers and the home. Unfractionated heparin, the anticoagulant of choice for many years, is now being replaced by low-molecular-weight heparins (LMWHs) in an expanding number of countries. This trend is attributable to the ease and convenience of the administration of LMWHs coupled with their reliability and predictability of dosing. However, the choice of which LMWH to use depends on the duration and frequency of the dialysis sessions. For patients who are allergic to heparin or have heparin-induced thrombocytopenia, alternative anticoagulants--the direct thrombin inhibitors and heparinoids--are now available. These agents either have short half-lives (and therefore need to be delivered by infusions), or prolonged half-lives, which allows simple bolus administration, but increases the risk of drug accumulation, overdosage and hemorrhage. In patients at risk of bleeding, regional anticoagulants enable anticoagulation to be limited to the extracorporeal circuit. Prostanoids and nafamostat mesilate are expensive regional anticoagulants, and citrate infusions add complexity to the procedure. A citrate-based dialyzate has now been introduced that might enable heparin-free dialysis or reduce systemic anticoagulant requirements.